Mode
Text Size
Log in / Sign up
Phase 2 N=170 Randomized Double-blind Treatment

A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)

Sarcopenia

Enrolled (actual)
170
Serious AEs
12.4%
Results posted
Jul 2012
Primary outcome: Primary: Change From Baseline in Participant Lean Body Mass — 1.26; 0.29 kg

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Comparator: MK-0773 (Drug); Comparator: Placebo (Drug)
Age
Older Adult · 65+ yrs
Sex
Female
Sponsor
Merck Sharp & Dohme LLC
Primary completion
Oct 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Participant Lean Body Mass
1.26; 0.29
PRIMARY
Change From Baseline in Bilateral Leg Press (BLP) Measurement
17.42; 15.95
SECONDARY
Change From Baseline in Participant Short Physical Performance Battery (SPPB)
0.92; 0.88
SECONDARY
Change From Baseline in Participant Gait Speed
6.24; 8.91
SECONDARY
Change From Baseline in Stair Climbing Power
19.68; 14.98
SECONDARY
Change From Baseline in Activity Measure for Post Acute Care (AM-PAC) Physical Movement Score
59.79; 59.13; 2.52; 2.38

Summary

A study to evaluate the safety, tolerability, and efficacy of MK-0773 in women with sarcopenia (loss of muscle mass).

Eligibility Criteria

Inclusion Criteria

  • Patient is a woman who is 65 years of age or older
  • Patient's lean body mass is at least 1 standard deviation below the mean of a healthy young adult population
  • Patient has difficulty climbing 10 steps or walking outside on level ground for 1/4 mile without resting or Activity Measure for Post Acute Care (AM-PAC)<66

Exclusion Criteria

  • Patient has serious neurological, rheumatologic, cardiac, respiratory, kidney, psychiatric conditions
  • Patient has a history of certain types of cancer
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00529659). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search